United States v. Prather

205 F.3d 1265
CourtCourt of Appeals for the Eleventh Circuit
DecidedMarch 7, 2000
Docket98-9094
StatusPublished

This text of 205 F.3d 1265 (United States v. Prather) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Prather, 205 F.3d 1265 (11th Cir. 2000).

Opinion

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT FILED __________________________ U.S. COURT OF APPEALS ELEVENTH CIRCUIT MAR 07 2000 No. 98-9094 THOMAS K. KAHN __________________________ CLERK

D.C. Docket No. 97-00171-1-CR-2-JOF

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

VERNON VICTOR PRATHER,JR., a.k.a. “Billy”,

Defendant-Appellant.

__________________________

Appeal from the United States District Court for the Northern District of Georgia __________________________

(March 7, 2000)

Before CARNES, BARKETT, and MARCUS, Circuit Judges.

BARKETT, Circuit Judge:

Vernon Victor Prather appeals his conviction for conspiracy to distribute

pseudoephedrine in violation of 21 U.S.C. §§ 861(d)(2) and 846, distribution of pseudoephedrine in violation of 21 U.S.C. § 841(d)(2) and 18 U.S.C. § 2, and

money laundering in violation of 18 U.S.C. §§ 2 and 1957(a). Prather asks this

Court to discharge him, vacating his conviction and sentence or, alternatively, to

grant him a new trial. We affirm Prather’s conviction and sentence, with the

exception of the imposition of the special assessment.

BACKGROUND

Prather was president and sole stockholder of X-Pressive Looks, Inc.

(“XLI”), a Florida-based mail-order corporation with offices in Florida, Georgia,

and California. XLI distributed miscellaneous items, including over-the-counter

pharmaceuticals. During 1994 and 1995, approximately 80% of XLI’s business

was derived from the distribution of pseudoephedrine, which is commonly

marketed as a nasal decongestant. Pseudoephedrine is also a “listed chemical”

under 21 U.S.C. §§ 802(33) and 802(34), and 21 C.F.R. § 1310.02(a)(11), because

it can be used as an ingredient to manufacture methamphetamine, a controlled

substance. XLI generally distributed pseudoephedrine in cases containing 75

bottles, each containing 1,000 tablets. Between April 1994 and August 1995, XLI

distributed more than 830 million tablets of pseudoephedrine to 173 wholesale

customers, including several “head shops” and numerous individuals. The vast

2 majority of those customers lacked business licenses, and many had the

pseudoephedrine shipped directly to their home addresses.

At trial, the government presented evidence that, beginning in September

1994, Prather knew from numerous sources that his product was being diverted

from the legitimate market for the illegal manufacture of methamphetamine. In

addition to other evidence, the jury heard testimony from Alberto Saa that in late

1994 or early 1995, he contacted Prather at XLI about purchasing 100 cases of

pseudoephedrine per week, to be shipped to his home address. He testified that

Prather informed him that such an arrangement “wasn’t a good idea” because the

“cops would be hot on” both Prather and Saa, and instructed Saa to buy from one

of XLI’s “head shop” customers instead.

The government also presented testimony that Prather specifically knew that

in 1994 and 1995, several of his customers were investigated by law enforcement

agencies and had pseudoephedrine shipments seized by authorities. Prather

continued to sell shipments to these customers after the seizure. In May 1995,

Prather obtained from a law firm an opinion letter advising Prather that selling

millions of pseudoephedrine tablets to small outlets might be considered prima

facie evidence of an intent to violate the law. On May 31, 1995, the DEA executed

search warrants at XLI’s Atlanta offices, seizing, among other items, more than

3 500 cases of pseudoephedrine. After the search, XLI significantly raised the price

of its pseudoephedrine, and its customers continued to buy hundreds of cases.

Finally, Prather’s sales manager Daniel Matta, who was also indicted, pled guilty

to the charges against him and testified against Prather at Prather’s trial.

Prather was ultimately convicted of: 1) one count of violating 21 U.S.C. §

846 by conspiring to distribute pseudoephedrine, a listed chemical, knowing or

having reasonable cause to believe that the chemical would be used to manufacture

a controlled substance; 2) ten counts of violating 21 U.S.C. § 841(d)(2) by actually

distributing pseudoephedrine, knowing or having reasonable cause to believe that it

would be used to manufacture a controlled substance; and 3) five counts of

violating 18 U.S.C. §§ 2 and 1957 by engaging in monetary transactions in

criminally derived property in excess of $10,000. He was sentenced to a 14 year

term of incarceration, followed by 3 years of supervised release. He was ordered

to pay a fine of $175,000 and a special assessment of $100 for each of the sixteen

counts on which he was convicted. Prather appeals his conviction and the

imposition of the special assessment.

DISCUSSION

Prather’s convictions for conspiracy and money laundering are predicated on

his convictions under 18 U.S.C. § 241(d)(2) for distributing pseudoephedrine

4 knowing or having reasonable cause to believe that the pseudoephedrine would be

used to manufacture methamphetamine. Section 841(d) provides that:

Any person who knowingly or intentionally -- . . . (2) possesses or distributes a listed chemical knowing, or having reasonable cause to believe, that the listed chemical will be used to manufacture a controlled substance . . . shall be fined . . . or imprisoned.

Prather challenges his conviction and sentence on several grounds. First, he

contends that the government failed to prove that the listed chemicals he sold were

actually used to manufacture a controlled substance, which he claims constitutes an

element of the crime. Second, he contends that the district court judge’s jury

instructions were so erroneous as to justify overturning his conviction or granting a

new trial. Third, he argues that the judge’s refusal to allow the defense to play a

previously recorded tape of a government witness during cross-examination

violated the Confrontation Clause and the Federal Rules of Evidence. Finally,

Prather argues that the trial judge violated the Federal Sentencing Guidelines and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Tokars
95 F.3d 1520 (Eleventh Circuit, 1996)
Mills v. Singletary
161 F.3d 1273 (Eleventh Circuit, 1998)
Montgomery v. Noga
168 F.3d 1282 (Eleventh Circuit, 1999)
United States v. Patrick Green
779 F.2d 1313 (Seventh Circuit, 1985)
United States v. Edward Washington
858 F.2d 590 (Tenth Circuit, 1988)
United States v. Johnny Rivera, Elena Vila
944 F.2d 1563 (Eleventh Circuit, 1991)
United States v. Charles Hyde
977 F.2d 1436 (Eleventh Circuit, 1992)
United States v. Evans H. Starke, Jr.
62 F.3d 1374 (Eleventh Circuit, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
205 F.3d 1265, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-prather-ca11-2000.